Xeris Biopharma Holdings (XERS) Gains from Investment Securities (2020 - 2026)

Xeris Biopharma Holdings has reported Gains from Investment Securities for 7 years, with the latest figure at $17.0 million in Q1 2026.

• For the quarter ending Q1 2026, Gains from Investment Securities rose 112.77% year-over-year to $17.0 million; the trailing twelve-month figure through Mar 2026 stood at $19.9 million (up 139.76% YoY), and the FY2025 full-year result was $10.9 million, up 191.27% from the prior year.
• Gains from Investment Securities for Q1 2026 stood at $17.0 million, up from $1.5 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $20.0 million in Q2 2023, with the low at -$236000.0 in Q4 2022.
• Historically, Gains from Investment Securities has averaged $3.8 million across 5 years, with a median of $669000.0 in 2025.
• Annual changes were most pronounced in 2024 — Gains from Investment Securities sank 99.75% — and 2025, when it surged 1586.27%.
• Xeris Biopharma Holdings' Gains from Investment Securities stood at -$236000.0 in 2022, then soared by 120.76% to $49000.0 in 2023, then jumped by 238.78% to $166000.0 in 2024, then soared by 827.71% to $1.5 million in 2025, then surged by 1005.0% to $17.0 million in 2026.
• The last three Gains from Investment Securities figures came in at $17.0 million (Q1 2026), $1.5 million (Q4 2025), and $478000.0 (Q3 2025), per Business Quant data.